TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05836792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle Ergometer
Description: Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercises
Description: The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
Study: NCT06385067

Intervention type: DEVICE
Intervention: Biolimus Coated Coronary Artery Balloon Dilation Catheter
Description: Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
Study: NCT05044052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emphasis on the Choosing Wisely Viral Prescription Pad
Description: We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
Study: NCT05100641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-GBM-1
Description: Therapeutic autologous dendritic cell vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous monocytes
Description: Autologous monocyte control
Study: NCT05455957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: neuromuscular and vestibulo-ocular training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: neuromuscular and vestibulo-ocular training
Study: NCT05349240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloonTM Ablation System.
Description: Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
Study: NCT05089734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously
Study: NCT05815511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: Oral capsule consumption once a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule consumption once a day for 12 weeks
Study: NCT05604378

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: All patients in our study underwent gastrectomy.

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: All patients in our study underwent gastrectomy.
Study: NCT02492932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasonography evaluation of the internal jugular vein.
Study: NCT05730400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMAC loaded on bovine graft
Description: Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine graft only
Description: Bovine graft only for sinus floor augmentation
Study: NCT05417958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extremely thick blenderized tube feed
Description: Commercial blenderized tube feed, not diluted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extremely thick blenderized tube feed
Description: Commercial blenderized tube feed, not diluted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extremely thick blenderized tube feed
Description: Commercial blenderized tube feed, not diluted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extremely thick blenderized tube feed
Description: Commercial blenderized tube feed, not diluted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mildly thick blenderized tube feed
Description: Commercial blenderized tube feed, diluted with ingredients contained in blend

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mildly thick blenderized tube feed
Description: Commercial blenderized tube feed, diluted with ingredients contained in blend

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mildly thick blenderized tube feed
Description: Commercial blenderized tube feed, diluted with ingredients contained in blend

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mildly thick blenderized tube feed
Description: Commercial blenderized tube feed, diluted with ingredients contained in blend
Study: NCT04801628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Tecar
Description: Active Tecar

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tecar
Description: Placebo Tecar
Study: NCT05239520

Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography and ultrasound
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles

Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography and ultrasound
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
Study: NCT05425381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced version of Interconnected Systems Framework
Description: * District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~* Detailed memoranda of understanding between schools and collaborating mental health centers~* Community mental health clinicians meaningfully participate in MTSS teams~* Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~* Universal screening of students' social, emotional, behavioral, and academic functioning~* Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~* Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~* Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~* A Community of Practice (Wenger, 2010) among the ISFE schools

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Behavioral Interventions and Supports with Co-located School Mental Health
Description: * PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai \& Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~* SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010).
Study: NCT06114979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silodosin
Description: Each patient will receive 8 mg of silodosin tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will receive placebo tablet.
Study: NCT05508555

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperthermic intrathoracic chemotherapy
Description: application of chemotherapeutic agent intrathoracic under hyperthermic conditions
Study: NCT04623645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound technique
Description: evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound technique
Description: evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
Study: NCT06054295

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Collection of both blood and saliva samples from participants at the time of study enrollment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
Study: NCT05816863

Intervention type: DRUG
Intervention: pabolizumab
Description: pabolizumab IV every 3 weeks (q3w)
Study: NCT05708391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo Naturalis Formulation
Description: Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT05825872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal superior laryngeal nerve block
Description: A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 0.5 ml will be injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% Injectable Solution
Description: 1.5 ml will be injected
Study: NCT00874302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: One 25mg capsule taken orally once every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Two 25mg capsules Proellex (50mg) taken orally once every day
Study: NCT06139991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BDA MDI HFO)
Description: Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BDA MDI HFO)
Description: Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BDA MDI HFO)
Description: Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
Study: NCT04869800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-398
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-398
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745
Description: Reference Drug
Study: NCT06002503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venezuelan Equine Encephalitis DNA Vaccine
Description: Venezuelan Equine Encephalitis DNA Vaccine Candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venezuelan Equine Encephalitis DNA Vaccine
Description: Venezuelan Equine Encephalitis DNA Vaccine Candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venezuelan Equine Encephalitis DNA Vaccine
Description: Venezuelan Equine Encephalitis DNA Vaccine Candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venezuelan Equine Encephalitis DNA Vaccine
Description: Venezuelan Equine Encephalitis DNA Vaccine Candidate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Stratis Needle-free Injection System
Description: Intramuscular Needle-free Injection System (Jet Injector)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Stratis Needle-free Injection System
Description: Intramuscular Needle-free Injection System (Jet Injector)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis Needle-free Injection System
Description: Intradermal Needle-free Injection System (Jet Injector)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis Needle-free Injection System
Description: Intradermal Needle-free Injection System (Jet Injector)
Study: NCT05960292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic and Vaginal Hysterectomy
Description: To make a comparison between the Vaginal Vault complications after Hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic and Vaginal Hysterectomy
Description: To make a comparison between the Vaginal Vault complications after Hysterectomy
Study: NCT06548646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Interfascial Plane Block
Description: The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
Study: NCT06571110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Acupuncture
Description: Acupuncture is a type of treatment where thin needles are gently inserted into specific parts of your body. It's often used to help with things like pain, headaches, stress, and anxiety.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture in this trial involves the insertion superficially to mimic the procedure of true acupuncture without providing any therapeutic effect. The needles will be similar to those used in the true acupuncture group but will not be stimulated, ensuring blinding and controlling for placebo effects.
Study: NCT06139991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BDA MDI HFA)
Description: Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BDA MDI HFA)
Description: Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BDA MDI HFA)
Description: Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
Study: NCT06375343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-240
Description: -Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive®
Description: - Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.
Study: NCT04908839

Intervention type: OTHER
Intervention: spot-25 questionnaire
Description: spot-25 questionnaire

Intervention type: OTHER
Intervention: spot-25 questionnaire
Description: spot-25 questionnaire

Intervention type: OTHER
Intervention: spot-25 questionnaire
Description: spot-25 questionnaire
Study: NCT06526702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Description: FX CorDiax 100 dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Description: FX CorDiax 100 dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration
Description: FX CorDiax 1000 dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration
Description: FX CorDiax 1000 dialyzer
Study: NCT05548959

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pneumatonometry after microshunt implantation
Description: Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pneumatonometry after ab interno trabeculectomy
Description: Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
Study: NCT05279430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
Study: NCT06152588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: 3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions.~9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives.
Study: NCT05167448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES104
Description: ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES104
Description: ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES104
Description: ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study: NCT04823351

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Surgical Mask
Description: The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Surgical Mask
Description: The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
Study: NCT05207878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STEGA-MRI
Description: Precision drawing task (movement assessment)